medsovetМедицинский СоветMeditsinskiy sovet = Medical Council2079-701X2658-5790REMEDIUM GROUP Ltd.10.21518/2079-701X-2017-1-144-148medsovet-1693Research ArticleГАСТРОЭНТЕРОЛОГИЯGASTROENTEROLOGYСОВРЕМЕННЫЕ ПРЕДСТАВЛЕНИЯ О ПРИМЕНЕНИИ ПРОБИОТИКОВ В ДЕТСКОЙ ПРАКТИКЕModern ideas about the use of probiotics in pediatric practiceКорниенкоЕ. А.KornienkoE. A.

д.м.н., профессор

MD, Prof.

Санкт-Петербургский государственный педиатрический медицинский университетРоссияSaint-Petersburg State Pediatric Medical UniversityRussian Federation20173012201701144148Copyright © Корниенко Е.А., 20172017Корниенко Е.А.Kornienko E.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-sovet.pro/jour/article/view/1693

Пробиотики – широко применяемые препараты с доказанным эффектом, которые улучшают здоровье организма хозяина. Они отличаются по составу, поэтому их выбор следует проводить на основании результатов проведенных ранее клинических исследований. Механизмы действия пробиотиков не сводятся к простому заселению кишечника, они оказывают антагонистическое действие по отношению к патогенам, укрепляют барьерные функции кишечника, стимулируют иммунную защиту, формируют иммунологическую толерантность. Показания к их назначению весьма широки: это острые кишечные инфекции, антибиотико-ассоциированная диарея, функциональные расстройства ЖКТ, лечение хронических инфекций и воспалительных заболеваний кишечника, профилактика аллергических заболеваний и инфекций у часто болеющих детей. Рациональный выбор пробиотика зависит от возраста, так как структура заболеваний и цели назначения пробиотиков в разных возрастных группах могут отличаться. Пробиотики Примадофилус для детей раннего и старшего возраста предусматривают эти особенности.

Probiotics are widely used drugs with the proven effect that improve the health of the host organism. They differ in composition, therefore their choice should be based on the results of past clinical trials. Mechanisms of action of probiotics are not limited to simple colonization of the intestine, they exert antagonistic action against pathogens, strengthen the barrier function of the intestine, stimulate the immune defense and form immunological tolerance. Indications for their purpose is very broad: it is an acute intestinal infection, antibiotic-associated diarrhea, functional gastrointestinal disorders, treatment of chronic infections and inflammatory bowel diseases, prevention of allergic diseases and infections in frequently ill children. A rational choice of a probiotic depends on the age, as the disease structure and the purpose of the probiotics in different age groups may vary. The probiotic Primadophilus for infants and older children provides these features.

пробиотикиПримадофилусдетиprobioticsPrimadophiluschildrenReferencesLilly DM, Stillwell RH. Probiotics: growth-promoting factors produced by microorganisms. Science, 1965, 147: 747–8.Lilly DM, Stillwell RH. Probiotics: growth-promoting factors produced by microorganisms. Science, 1965, 147: 747–8.Parker RB. Probiotics, the other half of the antibiotic story. Animal Nutr Health, 1974, 29: 4–8.Parker RB. Probiotics, the other half of the antibiotic story. Animal Nutr Health, 1974, 29: 4–8.FAO/WHO. Working group on drafting guidelines for the evaluation of probiotics in food. Guidelines for the evaluation of probiotics in food. 2002. ftp://ftp.fao.org/es/esn/food/wgreport2.pdf.FAO/WHO. Working group on drafting guidelines for the evaluation of probiotics in food. Guidelines for the evaluation of probiotics in food. 2002. ftp://ftp.fao.org/es/esn/food/wgreport2.pdf.Madsen K, Jijon H, Jeung H et al., DNA from probiotic bacteria exerts anti-inflammatory action on epithelial cells by inhibition of NF-kB. Gastroenterology, 2002, 122: A-64.Madsen K, Jijon H, Jeung H et al., DNA from probiotic bacteria exerts anti-inflammatory action on epithelial cells by inhibition of NF-kB. Gastroenterology, 2002, 122: A-64.Probiotic bacteria in dietetic products for infants: a commentary by the ESPGHAN Committee on Nutrition. J. Pediatr. Gastroenterol. Nutr., 2004, 38: 365-374.Probiotic bacteria in dietetic products for infants: a commentary by the ESPGHAN Committee on Nutrition. J. Pediatr. Gastroenterol. Nutr., 2004, 38: 365-374.Cruchet S, Furoes R, Maruy A et al. The use of probiotics in pediatric gastroenterology: A review of literature and recommendations by Latin-American experts. Pediatr. Drugs, 2015 Jun, 17(3): 199-216. DOI 10.1007/s40272-015-0124-6.Cruchet S, Furoes R, Maruy A et al. The use of probiotics in pediatric gastroenterology: A review of literature and recommendations by Latin-American experts. Pediatr. Drugs, 2015 Jun, 17(3): 199-216. DOI 10.1007/s40272-015-0124-6.Borchers AT et al. Probiotics and immunity. J Gastroenterol, 2009, 4: 26-46.Borchers AT et al. Probiotics and immunity. J Gastroenterol, 2009, 4: 26-46.Supplementation of infant formula with probiotics and/or prebiotics: a systemic rewiew and com￾ment by the ESPGHAN Commitee on Nutrition. J. Pediatr. Gastroenterol., 2011, 52(2): 238-250.Supplementation of infant formula with probiotics and/or prebiotics: a systemic rewiew and com￾ment by the ESPGHAN Commitee on Nutrition. J. Pediatr. Gastroenterol., 2011, 52(2): 238-250.Bezkorovainy A. Probiotics: determinants of survival and growth in the gut. Am. J. Clin. Nutr., 2001, 73(2): 399s-405s.Bezkorovainy A. Probiotics: determinants of survival and growth in the gut. Am. J. Clin. Nutr., 2001, 73(2): 399s-405s.General report of the Scientific Committee on Food of European Commission on the revision of essential requirements of infant formulas and follow-up formulas, 2003. http://europa. en.int/comm/food/fs/sc/scf/index.en.html.General report of the Scientific Committee on Food of European Commission on the revision of essential requirements of infant formulas and follow-up formulas, 2003. http://europa. en.int/comm/food/fs/sc/scf/index.en.html.Mercenier A, Pavan S, Pot B. Probiotics as biotherapeutic agents: present knowledge and future prospects. Curr. Pharm. Des., 2003, 9(2): 175-191.Mercenier A, Pavan S, Pot B. Probiotics as biotherapeutic agents: present knowledge and future prospects. Curr. Pharm. Des., 2003, 9(2): 175-191.Borriello SP et al. Safety of probiotics that contain lactobacilli or bifidobacteria. Clin Infect Dis, 2003, 36: 775-780.Borriello SP et al. Safety of probiotics that contain lactobacilli or bifidobacteria. Clin Infect Dis, 2003, 36: 775-780.Karpa KD. Probiotics for Clostridium difficile diarrhea: putting it into perspective. Ann Pharmacother., 2007, 41: 1284–1287.Karpa KD. Probiotics for Clostridium difficile diarrhea: putting it into perspective. Ann Pharmacother., 2007, 41: 1284–1287.Ng SC, Hart AL, Kamm MA et al. Mechanisms of action of probiotics: recent advances. Inflamm. Bowel Dis., 2009, 15(2): 301-312.Ng SC, Hart AL, Kamm MA et al. Mechanisms of action of probiotics: recent advances. Inflamm. Bowel Dis., 2009, 15(2): 301-312.Resta-Lenert S, Barrett KE. Live probiotics protect intestinal epithelial cells from the effects of infection. Gut, 2003, 52(7): 988-997.Resta-Lenert S, Barrett KE. Live probiotics protect intestinal epithelial cells from the effects of infection. Gut, 2003, 52(7): 988-997.Spinler JK, Tawelchotipatr M, Rognerud CL et al. Human-derived probiotic Lactobacillus reuteri demonstrate antimicrobial activities targeting diverse enteric bacterial pathogens. Anaerobe, 2008, 14: 166-171.Spinler JK, Tawelchotipatr M, Rognerud CL et al. Human-derived probiotic Lactobacillus reuteri demonstrate antimicrobial activities targeting diverse enteric bacterial pathogens. Anaerobe, 2008, 14: 166-171.Juntunen M, Kirjavainen PV. Ouwehand AC. Salminen SJ. Isolauri E. Adherence of probiotic bacteria to human intestinal mucus in healthy infants and during rotavirus infection. Clin Diagn Lab Immunol, 2001, 8(2): 293-6.Juntunen M, Kirjavainen PV. Ouwehand AC. Salminen SJ. Isolauri E. Adherence of probiotic bacteria to human intestinal mucus in healthy infants and during rotavirus infection. Clin Diagn Lab Immunol, 2001, 8(2): 293-6.Rakoff-Naboum S, Paglimo J, Eslami-Varzanch F et al. Recognition of commensal microflora by toll-like receptors is required for intestinal homeostasis. Cell, 2004, 118: 229-241.Rakoff-Naboum S, Paglimo J, Eslami-Varzanch F et al. Recognition of commensal microflora by toll-like receptors is required for intestinal homeostasis. Cell, 2004, 118: 229-241.Yan F, Polk DB. Probiotic bacterium prevents cytokine-induced apoptosis in intestinal epithelial cells. J. Biol. Chem., 2002, 277: 50959-50965.Yan F, Polk DB. Probiotic bacterium prevents cytokine-induced apoptosis in intestinal epithelial cells. J. Biol. Chem., 2002, 277: 50959-50965.Ouwehand A, Isolauri E, Salminen S. The role of intestinal microflora for development of the immune system in early childhood. Eur. J. Nutr., 2002, 41(1): 132-137.Ouwehand A, Isolauri E, Salminen S. The role of intestinal microflora for development of the immune system in early childhood. Eur. J. Nutr., 2002, 41(1): 132-137.Righy R, Kamm MA, Knight SC et al. Pathogenic bacteria stimulate colonic dendritic cells to produce pro-inflammatory IL-12 while the response to probiotic bacteria is to produce anti-inflammatory IL-10. Gut, 2002, 50: A70.Righy R, Kamm MA, Knight SC et al. Pathogenic bacteria stimulate colonic dendritic cells to produce pro-inflammatory IL-12 while the response to probiotic bacteria is to produce anti-inflammatory IL-10. Gut, 2002, 50: A70.Smits HH, Engering A, van Der KD et al. Selective probiotic bacteria induce IL-10- producing regulatory T cells in vitro by modulating dendritic cell function through dendritic cell-specific intercellular adhesion molecule 3-grabbing nonintegrin. J. Allergy Clin. Immunol., 2005, 115: 1260-1267.Smits HH, Engering A, van Der KD et al. Selective probiotic bacteria induce IL-10- producing regulatory T cells in vitro by modulating dendritic cell function through dendritic cell-specific intercellular adhesion molecule 3-grabbing nonintegrin. J. Allergy Clin. Immunol., 2005, 115: 1260-1267.Houghteling PD,Walker WA. Why is initial bsterial colonization of the intestine important to infants’ and children’s health. J. Pediatr. Gasteroenterol. Nutr., 2015, 60(3): 294-307.Houghteling PD,Walker WA. Why is initial bsterial colonization of the intestine important to infants’ and children’s health. J. Pediatr. Gasteroenterol. Nutr., 2015, 60(3): 294-307.Braat H, van Den BJ, van Tol E et al. Lactobacillus rhamnosus induces peripheral hyporesponsiveness in stimulated CD4+ T cells via modulation of dendritic cell function. Am. J. Clin. Nutr., 2004, 80: 1618-1625.Braat H, van Den BJ, van Tol E et al. Lactobacillus rhamnosus induces peripheral hyporesponsiveness in stimulated CD4+ T cells via modulation of dendritic cell function. Am. J. Clin. Nutr., 2004, 80: 1618-1625.Dalmasso G, Cotrez F, Imbert V et al. Saccharomyces boulardii inhibits inflammatory bowel disease by trapping T cells in mesenteric lymph nodes. Gastroenterology, 2006, 131: 1812-1825.Dalmasso G, Cotrez F, Imbert V et al. Saccharomyces boulardii inhibits inflammatory bowel disease by trapping T cells in mesenteric lymph nodes. Gastroenterology, 2006, 131: 1812-1825.Fang H, Elina T, Heikki A et al. Modulation of humoral immune response through probiotic intake. Immunol. Med. Microbiol., 2000, 29: 47-52.Fang H, Elina T, Heikki A et al. Modulation of humoral immune response through probiotic intake. Immunol. Med. Microbiol., 2000, 29: 47-52.Ouwehand A, Isolauri E, Salminen S. The role of the intestinal microflora for the development of the immune system in early childhood. Eur. J. Nutr., 2002, 41(1): I32-137.Ouwehand A, Isolauri E, Salminen S. The role of the intestinal microflora for the development of the immune system in early childhood. Eur. J. Nutr., 2002, 41(1): I32-137.Savino F, Cordisco L, Tarasco V et al. Lactobacillus reuteri DSM 17938 in infantile colic: a randomized double-blind, placebo controlled trial. Pediatrics, 2010, 126: 526-533.Savino F, Cordisco L, Tarasco V et al. Lactobacillus reuteri DSM 17938 in infantile colic: a randomized double-blind, placebo controlled trial. Pediatrics, 2010, 126: 526-533.Topping DL, Clifton PM. Short-chain fatty acids and human colonic function. Phisiol. Rev., 2001, 81: 1031-1064.Topping DL, Clifton PM. Short-chain fatty acids and human colonic function. Phisiol. Rev., 2001, 81: 1031-1064.

The authors declare that there are no conflicts of interest present.